Симона Гласберг

Научные публикации

• Enhancer landscape of lung neuroendocrine tumors reveals regulatory and developmental signatures with potential theranostic implications
• PRRT in high-grade digestive neuroendocrine neoplasms (NET G3 and NEC)
• Use and perceived utility of [¹⁸ F]FDG PET/CT in neuroendocrine neoplasms: A consensus report from the European Neuroendocrine Tumor Society (ENETS) Advisory Board Meeting 2022
• Clinical characteristics of a large familial cohort with Medullary thyroid cancer and germline Cys618Arg RET mutation in an Israeli multicenter study
• In Response
• Impact of Single-Time-Point Estimates of ¹⁷⁷Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles
• Emerging therapies for advanced insulinomas and glucagonomas
• Pancreatic metastases in patients with neuroendocrine neoplasms: A multi-centre cohort study
• COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study
• Clinical and pathologic characteristics of appendiceal neuroendocrine neoplasms diagnosed during pregnancy
• A Comparison of Outcomes in Medullary Thyroid Carcinoma Patients With and Without a Preoperative Diagnosis: A Multicenter Retrospective Cohort Study
• Outcome of COVID-19 infections in patients with adrenal insufficiency and excess
• Deliberate Compensated Vasoplegia-A Novel Pharmaceutical Approach for Controlling Blood Pressure During Surgery for Pheochromocytoma
• Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1-2 cm in size: a retrospective, Europe-wide, pooled cohort study
• Plasma Progastrin-Releasing Peptide and Chromogranin A Assays for Diagnosing and Monitoring Lung Well-Differentiated Neuroendocrine Tumors: A Brief Report
• Prognostic Factors in Advanced Adrenocortical Carcinoma: Summary of a National Referral Center's 20 years of Experience
• miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L2
• European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease
• Practical lessons from treating medullary thyroid carcinoma patients harboring a RET-alteration: Pralsetinib-induced acute confusional state
• ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors
• Development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the PANNET module)
• Liquid biopsy reveals collateral tissue damage in cancer
• The Autophagy Inhibitor Chloroquine, Alone or in Combination with mTOR Inhibitors, Displays Anti-Tumor Effects in In Vitro and In Vivo Lung Carcinoid Models
• Safety and Efficacy of Peptide-Receptor Radionuclide Therapy in Elderly Neuroendocrine Tumor Patients
• Synoptic reporting of echocardiography in carcinoid heart disease (ENETS Carcinoid Heart Disease Task Force)
• Corrigendum to 'Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study' [European Journal of Cancer 154 (2021) 246-252]
• Simple model for estimation of absorbed dose by organs and tumors after PRRT from a single SPECT/CT study
• Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy
• Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study
• RADIONUCLIDE THERAPY OF NEUROENDOCRINE TUMORS - IMPROVEMENTS IN THE PROTOCOL FOR MEASUREMENT OF PATIENT RADIATION EXPOSURE
• Is local excision sufficient in selected grade 1 or 2 type III gastric neuroendocrine neoplasms?
• Efficacy and Safety of ¹⁷⁷Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study
• An Update on the Management of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH)
• Can a penalized-likelihood estimation algorithm be used to reduce the injected dose or the acquisition time in ⁶⁸Ga-DOTATATE PET/CT studies?
• VHL-Related Neuroendocrine Neoplasms And Beyond: An Israeli Specialized Center Real-Life Report
• Update in carcinoid heart disease - the heart of the matter
• Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era
• Distinctive features of pancreatic neuroendocrine neoplasms exhibiting an increment in proliferative activity during the course of the disease
• Multiple Endocrine Neoplasia Type 1 (MEN1) 5'UTR Deletion, in MEN1 Family, Decreases Menin Expression
• Preclinical drug studies in MEN1-related neuroendocrine neoplasms (MEN1-NENs)
• The effect of prophylactic surgery in survival and HRQoL in appendiceal NEN
• Health-related quality of life in neuroendocrine neoplasia: a critical review
• The prognostic value of lymph node ratio in Medullary thyroid carcinoma: A multi-center study
• Severe Symptomatic Hypernatremia in a Patient with Panhypopituitarism after Short-Term Discontinuation of Desmopressin
• Somatostatin Analogs Improve Respiratory Symptoms in Patients With Diffuse Idiopathic Neuroendocrine Cell Hyperplasia
• Long-term outcomes in MEN-1 patients with pancreatic neuroendocrine neoplasms: an Israeli specialist center experience
• Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma
• Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management
• PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3)
• Authors' Response to the Letter by Lamarca et al. Entitled "Temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration" Regarding "Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms"
• Comparison of Pheochromocytoma-Specific Morbidity and Mortality Among Adults With Bilateral Pheochromocytomas Undergoing Total Adrenalectomy vs Cortical-Sparing Adrenalectomy
• Carcinoid Syndrome: Updates and Review of Current Therapy
• Diagnostic and Management Challenges in Vasoactive Intestinal Peptide Secreting Tumors: A Series of 15 Patients
• Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms
• Endoscopic Ultrasound-Guided Radiofrequency Ablation: A New Therapeutic Approach for Pancreatic Neuroendocrine Tumors
• Clinico-pathologic and dynamic prognostic factors in sporadic and familial medullary thyroid carcinoma: an Israeli multi-center study
• Intractable Hypokalemia: a Red Herring for Rapidly Evolving Ectopic Cushing's Syndrome
• The prognosis and management of neuroendocrine neoplasms-related metastatic bone disease: lessons from clinical practice
• Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study
• Predictive power of the post-treatment scans after the initial or first two courses of [¹⁷⁷Lu]-DOTA-TATE
• Bilateral Medullary Thyroid Carcinoma in a 3-Year-Old Female Patient with Multiple Endocrine Neoplasia 2A Syndrome Undergoing Prophylactic Thyroidectomy: Should Current Guidelines Be Revised?
• Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN)
• Unmet Needs in Appendiceal Neuroendocrine Neoplasms
• Gastric Carcinoids
• Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
• Reducing the number of CTs performed to monitor personalized dosimetry during peptide receptor radionuclide therapy (PRRT)
• Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors
• Combining chloroquine with RAD001 inhibits tumor growth in a NEN mouse model
• Temporal Trends in the Presentation, Treatment, and Outcome of Medullary Thyroid Carcinoma: An Israeli Multicenter Study
• Hepatic intra-arterial therapies in metastatic neuroendocrine tumors: lessons from clinical practice
• Update in the Therapy of Advanced Neuroendocrine Tumors
• Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma
• Epigenetic pathway inhibitors represent potential drugs for treating pancreatic and bronchial neuroendocrine tumors
• Non-functioning pancreatic neuroendocrine tumors: Surgery or observation?
• ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues
• ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Biochemical Markers
• ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms. Systemic Therapy 2: Chemotherapy
• ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging
• ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents
• Diagnosing and Managing Carcinoid Heart Disease in Patients With Neuroendocrine Tumors: An Expert Statement
• ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors
• ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours
• ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation
• ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification
• The role of hepatic trans-arterial chemoembolization in metastatic medullary thyroid carcinoma: a specialist center experience and review of the literature
• Valve Replacement in Patients with Carcinoid Heart Disease: Choosing the Right Valve at the Right Time
• Vandetanib induces a marked anti-tumor effect and amelioration of ectopic Cushing's syndrome in a medullary thyroid carcinoma patient
• Abrogation of Autophagy by Chloroquine Alone or in Combination with mTOR Inhibitors Induces Apoptosis in Neuroendocrine Tumor Cells
• Appendiceal neuroendocrine neoplasms: diagnosis and management
• Pancreatic neuroendocrine tumors with transformation to insulinoma: an unusual presentation of a rare disease
• Carcinoid Heart Disease: From Pathophysiology to Treatment--'Something in the Way It Moves'
• Clinical features of pancreatic neuroendocrine tumors
• Laparoscopic resection of pancreatic neuroendocrine tumors
• Current concepts in the diagnosis and management of type 1 gastric neuroendocrine neoplasms
• Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis
• Metastatic type 1 gastric carcinoid: a real threat or just a myth?
• Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia
• Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?
• Laparoscopic resection of primary midgut carcinoid tumors
• Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study
• Current size criteria for the management of neuroendocrine tumors of the appendix: are they valid? Clinical experience and review of the literature
• New drugs in the therapy of neuroendocrine tumors
• Inhibition of mTOR in carcinoid tumors
• The role of cell lines in the study of neuroendocrine tumors
• Fulminant ectopic Cushing syndrome in a patient with metastatic neuroendocrine carcinoma and Crohn's disease
• Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma
• Total versus hemithyroidectomy for microscopic papillary thyroid cancer
• Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia and the associated lung neuroendocrine tumors: clinical experience with a rare entity
• Prognostic value of post-thyroidectomy thyroglobulin levels in patients with differentiated thyroid cancer
• Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas
• Clinical characteristics and outcome of familial nonmedullary thyroid cancer: a retrospective controlled study
• Anemia in a cohort of men with macroprolactinomas: increase in hemoglobin levels follows prolactin suppression
• The potential role of mTOR inhibitors in the treatment of endocrine tumors
• Clinically silent chromaffin-cell tumors: Tumor characteristics and long-term prognosis in patients with incidentally discovered pheochromocytomas
• Metastatic bronchial neuroendocrine tumor to the pineal gland: a unique manifestation of a rare disease
• The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells
• Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors
• Well-differentiated thyroid carcinoma: comparison of microscopic and macroscopic disease
• Unusual clinical presentations of giant prolactinomas
• Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours
• Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms
• The role of somatostatin analogues in the treatment of neuroendocrine tumours
• Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line
• Medullary thyroid cancer: a retrospective analysis of a cohort treated at a single tertiary care center between 1970 and 2005
• Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials